Market Research Logo

United States Histology And Cytology Market Outlook to 2024

United States Histology And Cytology Market Outlook to 2024

Summary

GlobalData’s new report, United States Histology And Cytology Market Outlook to 2024, provides key market data on the United States Histology And Cytology market. The report provides value, in millions of US dollars within market segments - Flow Cytometers, Immunmodulators, Monoclonal Antibodies, Polyclonal Antibodies and Tissue Typing Reagents

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Histology And Cytology market segments - Flow Cytometers, Immunmodulators, Monoclonal Antibodies, Polyclonal Antibodies and Tissue Typing Reagents
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United States Histology And Cytology market.
  • Key players covered include Beckman Coulter Inc, Becton Dickinson and Co and Thermo Fisher Scientific Inc.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Histology And Cytology Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Histology And Cytology Market, United States
3.1 Histology And Cytology Market, United States, Revenue ($m), 2010-2017
3.2 Histology And Cytology Market, United States, Revenue ($m), 2017-2024
3.3 Histology And Cytology Market, United States, Distribution Share by Revenue ($m), 2017
3.4 Histology And Cytology Market, United States, Company Share by Revenue ($m), 2017
4 Overview of Key Companies in United States, Histology And Cytology Market
4.1 Beckman Coulter Inc
4.1.1 Company Overview
4.2 Becton Dickinson and Co
4.2.1 Company Overview
4.3 Thermo Fisher Scientific Inc
4.3.1 Company Overview
4.4 F. Hoffmann-La Roche Ltd
4.4.1 Company Overview
4.5 Immucor, Inc.
4.5.1 Company Overview
4.6 Siemens Healthcare GmbH
4.6.1 Company Overview
4.7 Sysmex Corp
4.7.1 Company Overview
5 Histology And Cytology Market Pipeline Products
6 Financial Deals Landscape
6.1 Equity Offerings
6.1.1 Fluidigm Raises USD30 Million in Public Offering of Shares
6.1.2 Biostage Raises USD8 Million Public Offering of Shares
6.2 Venture Financing
6.2.1 Armune BioScience Raises USD0.5 Million in Venture Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 Jul 25, 2017: Catherine Estrampes appointed President & CEO of GE Healthcare Europe
7.1.2 Jun 23, 2017: Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
7.1.3 Jun 23, 2017: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA
7.1.4 Jun 12, 2017: Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery
7.1.5 Jun 05, 2017: Cortice Biosciences Announces Presentation of Final Results from the Dose Escalation Stage of a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma
7.1.6 Apr 18, 2017: Biostage Appoints Stephen F. Badylak DVM, PhD, MD, as Co-Chairman of Scientific Advisory Board
7.1.7 Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors
7.1.8 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe
7.1.9 Nov 30, 2016: ARUP Laboratories appoints new CMO and director of laboratories
7.2 Financial Announcements
7.2.1 Aug 14, 2017: Biostage Reports 2017 Second Quarter Financial Results
7.2.2 Aug 03, 2017: Fluidigm Announces Second Quarter Financial Results and Operational Progress
7.2.3 May 11, 2017: Biostage Reports 2017 First Quarter Financial Results and Provides Business Update
7.2.4 May 04, 2017: Fluidigm Announces First Quarter Financial Results
7.2.5 Mar 09, 2017: Biostage Reports 2016 Financial Results and Provides Business Update
7.2.6 Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017
7.2.7 Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results
7.2.8 Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year
7.2.9 Nov 28, 2016: Toshiba Medical Launches New MR System for Efficient and Standardized Cardiac Exams
7.2.10 Nov 10, 2016: Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update
7.2.11 Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results
7.3 Other Significant Developments
7.3.1 May 18, 2017: Abcam Makes Final Performance-Based AxioMx Milestone Payment
7.4 Product News
7.4.1 Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit
7.5 Strategy And Business Planning
7.5.1 Nov 01, 2016: GE Healthcare enhances single-use manufacturing capabilities with facility expansion and automation
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer
1.1 List of Tables
Table 1: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Table 2: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 3: Histology And Cytology Market, United States, Distribution Share by Revenue ($m), USD Constant, 2017
Table 4: Histology And Cytology Market, United States, Company Share by Revenue ($m), USD Constant, 2017
Table 5: Histology And Cytology Market Pipeline Products
Table 6: Fluidigm Raises USD30 Million in Public Offering of Shares
Table 7: Biostage Raises USD8 Million Public Offering of Shares
Table 8: Armune BioScience Raises USD0.5 Million in Venture Financing
Table 9: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
1.2 List of Figures
Figure 1: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 2: Histology And Cytology Market, United States, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 3: Histology And Cytology Market, United States, Company Share (%) 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report